688046 药康生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.6037.74711.91817.31617.028
总资产报酬率 ROA (%)2.9416.5799.95512.89512.024
投入资产回报率 ROIC (%)3.2207.12811.02215.36115.427

边际利润分析
销售毛利率 (%)64.52467.61171.38374.33072.037
营业利润率 (%)22.74426.30833.67636.38134.940
息税前利润/营业总收入 (%)21.20723.63530.69335.81535.168
净利润/营业总收入 (%)22.42725.54131.87831.72529.182

收益指标分析
经营活动净收益/利润总额(%)94.23284.35471.65772.40665.201
价值变动净收益/利润总额(%)11.7538.8325.4377.9797.746
营业外收支净额/利润总额(%)-0.010-1.488-0.1570.035-0.178

偿债能力分析
流动比率 (X)4.0884.5246.8533.6874.330
速动比率 (X)3.9624.3956.6223.5304.215
资产负债率 (%)19.16417.57212.24725.49125.583
带息债务/全部投入资本 (%)7.9926.4692.6255.665-0.053
股东权益/带息债务 (%)1,112.0591,389.3163,596.7631,552.634-168,913.827
股东权益/负债合计 (%)421.808469.088716.557292.300290.881
利息保障倍数 (X)-13.814-10.332-10.472-61.858121.343

营运能力分析
应收账款周转天数 (天)166.015131.518105.86095.648105.992
存货周转天数 (天)75.01486.25196.87484.41373.133